Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Yestar Aesthetic Medical / Equity Capital Markets

<p>Yestar, a leading aesthetic medical chain in China, is seeking to list in Hong Kong. In this insight, we will cover the following topics:</p>
<ul>
<li>The business lines of the company</li>
<li>Growth drivers</li>
<li>Risk of the business</li>
<li>Company history and shareholders</li>
<li>Initial thoughts on valuation</li>
</ul>
<p>We have seen red flags that we would simply pass the deal.</p>

Yestar, a leading aesthetic medical chain in China, is seeking to list in Hong Kong. In this insight, we will cover the following topics:

The business lines of the company
Growth drivers
Risk of the business
Company history and shareholders
Initial thoughts on valuation

We have seen red flags that we would simply pass the deal.

Yestar Aesthetic Medical (艺星医疗) IPO: Founders' Origin and Red Flags Matter

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Yestar Aesthetic Medical (YES HK)

Yestar Aesthetic Medical (艺星医疗) IPO: Founders' Origin and Red Flags Matter

Yestar, a leading aesthetic medical chain in China, is seeking to list in Hong Kong. In this insight, we will cover the following...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)